We provide Fractional Clinical & Regulatory Executive services for early-stage medical device companies, specializing in neuromodulation and AI-enabled platforms. Our work focuses on designing capital-efficient development pathways that withstand FDA scrutiny and investor due diligence. We support venture funds and startups in de-risking clinical and regulatory strategy from preclinical development through pivotal study execution.